Life Settlement Assets +(LSAA, House Stock at US$1.7) - Robust results

Life Settlement Assets +(LSAA, House Stock at US$1.55) - Notification of substantial maturities

Life Settlement Assets + (LSAA, House Stock at US$1.55) - Delivering uncorrelated returns

Life Settlement Assets + (LSAA, House Stock at $1.55) - Potential for higher returns

SHORE CAPITAL - Life Settlement Assets + (LSAA, House Stock at $1.46) - MBC acquisition completed, NAV uplift

SHORE CAPITAL - Life Settlement Assets+ (LSAA) - House Stock at $1.50

SHORE CAPITAL - Life Settlement Assets + (LSAA, House Stock at $1.46) - Dividends resumed, potential NAV uplift

SHORE CAPITAL - Life Settlement Assets + (LSAA) - House Stock at $1.4

SHORE CAPITAL - Life Settlement Assets + (LSAA) - House Stock at US$1.39

Trinity Delta Lighthouse: Avacta

Trinity Delta view: Prioritisation of the Therapeutics division continues, with Christina Coughlin’s appointment as CEO (having been on the Board since March 2022 and Head of R&D since February 2024). Once the Diagnostics division has been divested, Avacta will become a fully focused biotech company. This strategy is underpinned by the proprietary pre|CISION platform, and lead peptide drug conjugate AVA6000. Completion of the two-weekly safety study and progression into dose expansion cohorts du

Avacta Group - FY23 results, Chris Coughlin appointed CEO

Avacta reported results for FY23 but more importantly announced the appointment of Christina Coughlin as CEO wef 1 May, replacing Alastair Smith who is stepping down today. FY23 results were better than consensus at the EPS level. Net cash ended the year at £16.6m, as previously disclosed, which has since been bolstered by the £31m gross equity raise enabling Avacta to fund the AVA6000 programme through Phase 2 clinical trials, as well as advancing other candidates in its pre|CISION™ and Affime

Anexo Group (ANX LN) - Solid performance across divisions

Anexo has reported FY23 results, with a solid performance across the Group, boosted by the agreement of its first Emissions action in the year. Increased activity levels in Credit Hire and a large portfolio of claims in Legal Services underpin our forecasts, with the benefit of future Emissions Case agreements providing upside risk should settlements be reached.

Anexo Group - Solid FY23 results, significant net cash inflow, continuing opportunities for growth

This morning's FY results from ANX suggest that substantial growth opportunities remain in its three businesses in the credit hire and legal services areas, with these as ever serving high-demand markets. ANX is the UK market-leader in credit hire and legal services for impecunious no-fault motorists, while also operating Housing Disrepair and Vehicle Emissions litigation businesses. Last year, Credit Hire saw judicious management of the fleet during the period in order to make the best use of a

Pensacola appraisal well - funding challenges

AUCTUS ON FRIDAY - 03/05/2024

AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; target price of A$0.75 per share: Raising new equity to fund a high impact activity programme – ADX has raised A$13.5 mm of new equity priced at A$0.105 per share. One free-attaching option will be issued for evert two placement shares with an exercise price of A$0.15 per share and an expiry date of 08/05/2026. The proceeds from the raise will fund (1) the production testing of the 450 m gas column encountered at

Christie Group + (CTG, House Stock at 98p) - Difficult FY23A, future looks better

Northcoders - Inline results demonstrate record growth, strong fundamentals; FY24E starts well

Following on from the news, earlier in the year, of a conspicuous, £10m, contract win, this morning's FY23A results demonstrate rapid growth for the business last year, with revenues +27% YoY. 2023 was a year of investment for CODE, with a series of meaningful upgrades to the learning, marketing and administrative platforms leaving the business well-placed to develop profitably, as projected in our forecasts. Gross margin remained robustly above 60% and the company saw double digit increases bot

Hybridan Small Cap Feast - 01 May 2024

1st May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: REDX Pharma (REDX.L) has delisted from the AIM Market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing

UK's best rated holiday provider: still ~£4 too cheap to us

Hybridan Small Cap Feast - 03 May 24

3rd May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: TheWorks (WRKS.L) has transferred to AIM from the Premium Segment of the Main Market. Electric Guitar (ELEG.L) has transferred to AIM from the Standard Segment of the Main Market. Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Tak

Hostelworld Group - Backpacking them in

Hostelworld’s pioneering and fast-evolving ‘social’ strategy is delivering aplenty. Material outperformance of the hostel market (FY23 bed nights sold up 30% vs industry 8%) and low-cost acquisition and retention of high-value customers (over a million social members after just 18 months) confirm the success of the company’s app-centric model, which taps into the social media habits of its target demographic to mutual benefit. With reducing marketing percentage of revenue on track to meet the FY

Elixirr - Outperforming competitors and the global Consulting market

Elixirr offers investors exposure to the long-term growth trends in the global Consulting market (including digitisation and the ongoing technology revolution, demand for innovation, efficiency and specialised expertise) all turbo charged by the group’s ‘challenger’ strategy driving market share gain from a low base. FY 2023 results showed the power of Elixirr’s differentiated model with revenue up +20% and adj. EPS up +22% in a market subdued by global uncertainty. With net cash of £18m, a posi

hVIVO - Introducing 2025E; HSD sales grth/margin expansion expected

Post further analysis of the FY 2023 results on 9 April 2024, we are establishing FY 2025 forecasts, as well as modifying our forecast adjusted net profit/EPS figures for 2024 and 2025 to reflect the accounting of the deferred tax asset. Our 2025 forecast calls for 9% growth in customer revenues, stable other operating income (largely R&D tax credits) vs 2024, EBITDA margins going back to the 23% level (after a slight contraction in 2024 to reflect 3 facilities being run in parallel for part of

Allenby Capital TMT Update - 29.04.24 - SKL.L, ENET.L, CHSS.L

Please find below our weekly update covering themes that we feel that are of interest to investors and participants in the small and mid-cap TMT sector as well as commentary on recent newsflow.